Pfpl Inhibitors
Pfpl inhibitors pertain to a class of chemical compounds designed to selectively inhibit the function of a specific enzyme known as plasmodium falciparum phosphatidylinositol-4-phosphate 5-kinase (PfPI4K). This enzyme plays a crucial role in the life cycle of the Plasmodium falciparum parasite, which is responsible for a particular type of infection. The enzyme's primary function is to catalyze the conversion of phosphatidylinositol 4-phosphate (PI4P) to phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) on the cytoplasmic side of intracellular membranes. This biochemical reaction is a key step in the phosphatidylinositol pathway, which is involved in various intracellular processes, including membrane trafficking, signal transduction, and cytoskeletal dynamics. By targeting this enzyme, Pfpl inhibitors interfere with the production of vital lipid components that are essential for the parasite's intracellular survival and proliferation.
The molecular design of Pfpl inhibitors is focused on creating high-affinity interactions with the active site of the PfPI4K enzyme. This specificity is achieved through the careful design of the inhibitor's structure, which often involves the presence of a head group that mimics the natural substrate of the enzyme, allowing it to compete with the substrate for binding. The rest of the molecule is typically optimized to enhance the interaction with the enzyme's active site and surrounding regions, increasing the potency and selectivity of the inhibition. Additionally, Pfpl inhibitors are constructed to have favorable pharmacokinetic properties, ensuring they are stable and can effectively reach the enzyme within the cellular environment. The development of these inhibitors involves a combination of computational modeling, structure-activity relationship studies, and biochemical assays to fine-tune the inhibitor's interactions with the enzyme and to ensure specificity for PfPI4K over other kinases.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride is a diuretic that inhibits sodium channels in the distal nephron. Inhibition of these channels decreases sodium reabsorption, leading to reduced intracellular Na+, which indirectly could inhibit Pfpl by altering ion gradients. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cell growth and proliferation. By inhibiting mTOR, rapamycin may reduce the cellular resources necessary for Pfpl function, indirectly leading to its inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that interrupts the PI3K/Akt signaling pathway. Since the PI3K/Akt pathway is involved in cell survival and proliferation, LY294002 can indirectly inhibit Pfpl by dampening this survival pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that blocks the MAPK/ERK pathway. By preventing the activation of ERK, U0126 may decrease cell proliferation and differentiation signals, potentially leading to an indirect inhibition of Pfpl activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may indirectly inhibit Pfpl by blocking the response to stress stimuli and inflammation, leading to decreased cellular demand for Pfpl activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which influences apoptosis and cell survival. Inhibition of JNK signaling by SP600125 could reduce the pro-survival signals, indirectly affecting the functional requirements for Pfpl. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor that disrupts mitosis. By inhibiting Aurora kinase A, alisertib could reduce cell division rates, which might indirectly lead to a reduction in Pfpl activity due to decreased cellular turnover. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
IWP-2 is an inhibitor of the Wnt processing enzyme PORCN. It could indirectly inhibit Pfpl by altering Wnt signaling, which is involved in various cellular processes including cellular proliferation and differentiation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect multiple cellular pathways by preventing the degradation of proteins. This could lead to an indirect inhibition of Pfpl through the accumulation of regulatory proteins that inhibit Pfpl. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor that can prevent proper chromosome alignment and segregation during mitosis. This could indirectly inhibit Pfpl by disrupting normal cell division and the associated demand for Pfpl activity. | ||||||